Retrospective Study on Surgical Treatment of Medication-related Osteonecrosis of The Jaw

doi:10.13701/j.cnki.kqyxyj.2026.01.005

Abstract

Abstract: Objective: To summarize and analyze the clinical data of patients with medication-related osteonecrosis of the jaw (MRONJ) who underwent surgical treatment and to explore the impact of surgical methods and other factors on disease prognosis. Methods: A retrospective analysis was conducted on the data of 173 patients with stage 2-3 MRONJ who underwent surgery at Nanjing Stomatological Hospital from January 2013 to October 2024. Results: A total of 144 cases were cured and 29 cases relapsed. The overall cure rate was 83.2%, and the cure rate of the mandible was significantly lower than that of the maxilla (P<0.05). Bone tube technique (for refractory stage 2) and titanium plate reconstruction (for stage 3 mandible) significantly improved the cure rate (P<0.05), while there was no significant difference in prognosis for stage 3 maxilla with window drainage and subtotal resection (P>0.05). Conclusion: There is no significant gender difference in the incidence of MRONJ. The prognosis of surgery for mandibular MRONJ is worse than that for maxillary MRONJ. Bone tube technique and titanium plate reconstruction are key to improving prognosis.

Key words: medication-related osteonecrosis of the jaw, surgical treatment, prognosis, bone canal technique

WANG Rui, LI Fuyan, HE Jinyuan, SUN Guowen. Retrospective Study on Surgical Treatment of Medication-related Osteonecrosis of The Jaw[J]. Journal of Oral Science Research, 2026, 42(1): 22-29.

References

[1] Marx RE. Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: A growing epidemic[J]. J Oral Maxillofac Surg, 2003, 61(9):1115-1117.
[2] Ruggiero SL, Dodson TB, Aghaloo T, et al. American Association of Oral and Maxillofacial Surgeons position paper on medication-related osteonecrosis of the jaw-2022 update[J]. J Oral Maxillofac Surg, 2022, 80(5):920-943.
[3] 刘忠龙,姜钧健,李晓光,等.一种新的药物性颌骨坏死临床分期及治疗策略[J].中国口腔颌面外科杂志,2020,18(6):501-507.
[4] 郭玉兴,王佃灿,刘筱菁,等.翻瓣联合骨管技术拔牙方案在药物相关性颌骨坏死潜在风险患者中的应用初探[J].中华口腔医学杂志,2021,56(5):452-457.
[5] 田美,王丹妮,罗舒艳,等.上颌骨药物相关性颌骨坏死的手术治疗效果初探[J].中华口腔医学杂志,2021,56(5):447-451.
[6] 何悦,陈珩,安金刚,等.药物相关性颌骨坏死临床诊疗专家共识[J].中国口腔颌面外科杂志,2023,21(4):313-325.
[7] Shin JW, Kim JE, Huh KH, et al. Computed tomography imaging features of osteomyelitis of the jaw: comparison between antiresorptive medication-related conditions and medication-unrelated conditions[J]. Oral Surg Oral Med Oral Pathol Oral Radiol, 2020, 129(6):629-634.
[8] 高娜,田美,孙亚威,等.骨管技术在Ⅱ期下颌骨药物相关性颌骨坏死手术中的应用初探[J].华西口腔医学杂志,2024,42(5):629-635.
[9] Russmueller G, Seemann R, Weiss K, et al. The association of medication-related osteonecrosis of the jaw with Actinomyces spp. infection[J]. Sci Rep, 2016, 6:31604.
[10] Mu Y, Feiwu K, Xueming Z. Research progress on the at-risk category and stage 0 of medication-related osteonecrosis of the jaw[J]. J Oral Maxillofac Surg, 2025, 35:53.
[11] Park JH, Park W, Nguyen LP, et al. Treatment period and changes in bone markers according to the application of teriparatide in treating medication-r-elated osteonecrosis of the jaw[J]. BMC Oral Health, 2025, 25(1):528.
[12] 肖维维,陈媛丽,宗春琳,等.己酮可可碱和维生素E联合治疗放射性颌骨骨坏死的Meta分析[J]. 中华口腔医学研究杂志(电子版),2017,11(4):218-224.
[13] Otto S, Ristow O, Pache C, et al. Fluorescave-guided surgery for the treatment of medication-related ostenecrosis of the jaw: A prospective cohort study[J]. J Cranio-maxillofac Surg, 2016,44(8):1073-1080.
[14] Yoshiga D, Sasaguri M, Matsuo K, et al. Intraoperative detection of viable bone with fluorescence imaging using Visually Enhanced Lesion Scope in patients with bisphosphonate-related osteonecrosis of the jaw: clinical and pathological evaluation[J]. Osteoporos Int, 2015, 26(7):1997-2006.
[15] 郭玉兴,张建运,王佃灿,等.药物相关颌骨骨坏死的病理特点及临床治疗策略[J].北京大学学报(医学版),2022, 54(6):1190-1195.
[16] 周颖,赵宁,黄骇远,等.双层软组织缝合封闭技术在下颌骨中早期药物相关性颌骨骨坏死患者手术治疗中的应用[J].北京大学学报(医学版),2024, 56(1):51-56.
[17] 孙国文,田美.药物相关性颌骨坏死不同阶段治疗方法述评[J].口腔颌面外科杂志,2022,32(3):135-143.